Assignee
NOVALIQ GMBH
DE·36 granted patents·28 pending applications·464 citations·filing 2006–2025
Top patents by PatentIndex Score
64 records- 0197US12128010B2Semifluorinated compounds and their compositionsNOVALIQ GMBH·Filed 2022·Granted Oct 29, 2024·6 cites·13 claims
- 0297US11357738B2Semifluorinated compounds and their compositionsNOVALIQ GMBH·Filed 2020·Granted Jun 14, 2022·15 cites·18 claims
- 0397US11154513B2Semifluorinated compoundsNOVALIQ GMBH·Filed 2016·Granted Oct 26, 2021·20 cites·18 claims
- 0497US10682315B2Semifluorinated compounds and their compositionsNOVALIQ GMBH·Filed 2018·Granted Jun 16, 2020·21 cites·12 claims
- 0596US11583513B2Semifluorinated alkane compositionsNOVALIQ GMBH·Filed 2020·Granted Feb 21, 2023·10 cites·12 claims
- 0696US10369117B2Compositions comprising mixtures of semifluorinated alkanesNOVALIQ GMBH·Filed 2017·Granted Aug 6, 2019·18 cites·9 claims
- 0796US10058615B2Semifluorinated alkane compositionsNOVALIQ GMBH·Filed 2017·Granted Aug 28, 2018·26 cites·9 claims
- 0896US9770508B2Semifluorinated alkane compositionsNOVALIQ GMBH·Filed 2013·Granted Sep 26, 2017·47 cites·20 claims
- 0995US12005033B2Compositions comprising mixtures of semifluorinated alkanesNOVALIQ GMBH·Filed 2019·Granted Jun 11, 2024·6 cites·24 claims
- 1095US11987623B2Stabilized antibody compositionsNOVALIQ GMBH·Filed 2021·Granted May 21, 2024·5 cites·20 claims
- 1195US11324757B2Pharmaceutical composition for treatment of increased intraocular pressureNOVALIQ GMBH·Filed 2019·Granted May 10, 2022·7 cites·17 claims
- 1295US10576154B2Semifluorinated alkane compositionsNOVALIQ GMBH·Filed 2018·Granted Mar 3, 2020·17 cites·19 claims
- 1395US10555953B2Pharmaceutical composition for treatment of increased intraocular pressureNOVALIQ GMBH·Filed 2019·Granted Feb 11, 2020·15 cites·17 claims
- 1495US9757460B2Stabilised protein compositions based on semifluorinated alkanesNOVALIQ GMBH·Filed 2013·Granted Sep 12, 2017·39 cites·16 claims
- 1594US11400132B2Ophthalmic compositions comprising ciclosporinNOVALIQ GMBH·Filed 2020·Granted Aug 2, 2022·8 cites·14 claims
- 1694US10449164B2Methods of treating ocular disorders using semifluorinated alkanesNOVALIQ GMBH·Filed 2013·Granted Oct 22, 2019·22 cites·11 claims
- 1793US11273174B2Iodine compositionsNOVALIQ GMBH·Filed 2018·Granted Mar 15, 2022·17 cites·23 claims
- 1893US10813976B2Ophthalmic compositions comprising ciclosporinNOVALIQ GMBH·Filed 2017·Granted Oct 27, 2020·20 cites·15 claims
- 1992US12059449B2Ophthalmic composition for treatment of dry eye diseaseNOVALIQ GMBH·Filed 2022·Granted Aug 13, 2024·5 cites·17 claims
- 2092US11413323B2Ophthalmic composition for treatment of dry eye diseaseNOVALIQ GMBH·Filed 2021·Granted Aug 16, 2022·10 cites·22 claims
- 2192US8029977B2Method for preserving organs or limbs using a composition containing a siloxane and a semifluorinated alkane and/or hydrofluoroetherNOVALIQ GMBH·Filed 2006·Granted Oct 4, 2011·47 cites·23 claims
- 2291US11723861B2Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseasesNOVALIQ GMBH·Filed 2018·Granted Aug 15, 2023·7 cites·13 claims
- 2390US11684589B2Pharmaceutical compositions for use in the therapy of blepharitisNOVALIQ GMBH·Filed 2017·Granted Jun 27, 2023·6 cites·12 claims
- 2490US10507132B2Topical administration methodNOVALIQ GMBH·Filed 2017·Granted Dec 17, 2019·22 cites·17 claims
- 2590US10273298B2Stabilized antibody compositionsNOVALIQ GMBH·Filed 2014·Granted Apr 30, 2019·16 cites·14 claims
- 2688US12226422B2Ophthalmic compositions comprising tafluprost for the treatment of glaucomaNOVALIQ GMBH·Filed 2019·Granted Feb 18, 2025·6 cites·19 claims
- 2787US2025345276A1O/w-emulsions comprising semifluorinated alkanesNOVALIQ GMBH·Filed 2025·Application pending·0 cites
- 2886US11278503B2Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditionsNOVALIQ GMBH·Filed 2018·Granted Mar 22, 2022·7 cites·9 claims
- 2986US2025017872A1Semifluorinated compounds and their compositionsNOVALIQ GMBH·Filed 2024·Application pending·0 cites
- 3085US11896559B2Opthalmic compositions comprising F6H8NOVALIQ GMBH·Filed 2018·Granted Feb 13, 2024·7 cites·20 claims
- 3184US2024350425A1Compositions comprising mixtures of semifluorinated alkanesNOVALIQ GMBH·Filed 2024·Application pending·0 cites
- 3283US11576893B2Pharmaceutical compositions comprising nebivololNOVALIQ GMBH·Filed 2019·Granted Feb 14, 2023·7 cites·21 claims
- 3383US2023139672A1O/w-emulsions comprising semifluorinated alkanesNOVALIQ GMBH·Filed 2022·Application pending·0 cites
- 3481US2026091084A1Ophthalmic composition for treatment of dry eye diseaseNOVALIQ GMBH·Filed 2025·Application pending·0 cites
- 3581US2023330056A1Semifluorinated alkane compositionsNOVALIQ GMBH·Filed 2023·Application pending·0 cites
- 3678USRE50060ETopical administration methodNOVALIQ GMBH·Filed 2017·Granted Jul 30, 2024·5 cites·49 claims
- 3776US12569452B2Ophthalmic compositions comprising F6H8NOVALIQ GMBH·Filed 2024·Granted Mar 10, 2026·0 cites·21 claims
- 3873US12496326B2Ophthalmic composition for treatment of dry eye diseaseNOVALIQ GMBH·Filed 2022·Granted Dec 16, 2025·0 cites·16 claims
- 3971US2020360285A1O/w-emulsions comprising semifluorinated alkanesNOVALIQ GMBH·Filed 2020·Application pending·0 cites
- 4071US2024374678A1Ophthalmic composition for treatment of dry eye diseaseNOVALIQ GMBH·Filed 2024·Application pending·0 cites
- 4171US2022354926A1Ophthalmic compositions comprising ciclosporinNOVALIQ GMBH·Filed 2022·Application pending·0 cites
- 4270US2023398065A1Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseasesNOVALIQ GMBH·Filed 2023·Application pending·0 cites
- 4366US2019224123A1O/w-emulsions comprising semifluorinated alkanesNOVALIQ GMBH·Filed 2019·Application pending·0 cites
- 4464US2021315832A1Semifluorinated compoundsNOVALIQ GMBH·Filed 2021·Application pending·0 cites
- 4563USRE49758EStabilised protein compositions based on semifluorinated alkanesNOVALIQ GMBH·Filed 2013·Granted Dec 19, 2023·0 cites·35 claims
- 4663US2025295607A1Ophthalmic compositions for treatment of ocular surface damage and symptoms of drynessNOVALIQ GMBH·Filed 2025·Application pending·0 cites
- 4760US2022079925A1Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseasesNOVALIQ GMBH·Filed 2021·Application pending·0 cites
- 4857US2018360908A1Ophthalmic composition for treatment of dry eye diseaseNOVALIQ GMBH·Filed 2018·Application pending·0 cites
- 4957US2017087100A1Semifluorinated compounds and their compositionsNOVALIQ GMBH·Filed 2016·Application pending·0 cites
- 5056US12419933B2Ophthalmic composition for the treatment of uveitisNOVALIQ GMBH·Filed 2020·Granted Sep 23, 2025·0 cites·17 claims
Showing the top 50 of 64 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →